Kahn-Sagol-Maccabi (KSM) and Genetika+ form a research partnership to develop and validate AI that personalizes and speeds up an optimal depression treatment
TEL AVIV, ISRAEL, August 15, 2022 / EINPresswire. com / — Kahn-Sagol-Maccabi (KSM), the research plus innovation center of Israel’s Maccabi Healthcare Services, in addition to Genetika+, the pioneer in personalized medicine for the particular brain, are partnering to advance the development of tools in order to personalize depressive disorders treatment using Artificial Intelligence (AI) and even advanced analytics.
The collaboration between Genetika+ and KSM is focused on conducting large-scale state-of-the-art analysis on extensive data from patients suffering from depressive disorder in order to further develop together with validate Genetika+’s AI-based algorithms that help physicians treat patients with depression based on their individual characteristics.
Depression currently affects an estimated 300 million people worldwide. While many depression medications exist upon the market, individual responses vary significantly, and many people do not respond to drugs even after trying multiple medications. Today physicians generally rely on a new trial-and-error approach to deal with patients, leading to continued suffering and extensive side effects from the various drugs.
Combining AI solutions with advanced analytics and additionally rich information, such as patient medical history, co-morbidities, and polypharmacy, KSM not to mention Genetika+ aim to optimize the treatment process so that physicians can take care of patients more efficiently and effectively.
“We are usually facing some sort of surging mental health crisis around typically the world, across all ages, from children to be able to young adults and also through the elderly, alongside this rise associated with our technological advances as well as dependence inside COVID times, ” said Dr. Tal Patalon, head of KSM. “We must improve our early detection abilities, as well as our personalized treatment for mental health challenges while providing better comprehensive biopsychosocial support and treatment. ”
“We are particularly excited about this cooperation and often the ability to use the Maccabi data to support the optimization of therapy in major depression, ” stated Dr. Daphna Laifenfeld, co-founder and Chief Strategy Officer of Genetika+. ”The depth and richness of your Maccabi database are unique assets that will help us bring robust plus validated options to the exact clinic, to aid physicians in addition to bring relief and quality of life to individuals. ”
About Kahn-Sagol-Maccabi (KSM):
Kahn-Sagol-Maccabi (KSM) is the Research and even Innovation Center of Maccabi Healthcare Services, Israel’s leading HMO. KSM has distinctive access to Maccabi’s professional abilities and medical knowledge, including a large database of 2. 5 mil members along with 30 years regarding data collection. For more details, visit:
Genetika+, founded found in 2018 by Talia Cohen-Solal, Ph. D., and Daphna Laifenfeld, Ph. D., is developing customized medicine remedies to enhance treatment with regard to psychiatric together with neurological diseases. The company’s Brain-in-a-Dish technology helps doctors find the particular best remedy for their own patients. For more information, visit: https://www.genetikaplus.com/
[email protected]. us